NanoCarrier, Eisai deal

Eisai granted NanoCarrier an exclusive, worldwide license to develop and commercialize Eisai’s E7974 for cancer. NanoCarrier will use its antibody/drug-conjugated micelle (ADCM) technology, in which an antibody is conjugated to a micellular nanoparticle surface to improve antigen selection capabilities, to encapsulate the compound and enhance micelle accumulation in the lesion and reduce drug toxicity. NanoCarrier developed the technology under a 2012 research deal with Eisai. ...